| Tasly Research Institute was founded in 1994. After 25 years of exploration and accumulation, the original product development department has developed into a large health product research and development institution with complete supporting functions, reasonable talent structure and advanced equipment. The institute is located in Beichen Industrial Park, Tianjin, with a total laboratory area of 73,000 square meters. It has a research building, a pharmacological and toxicology building, and a chemical synthesis building, including a modern Chinese medicine development center, a chemical drug development center, a biological drug development center, and a health care food development center. , 5 product development centers such as Efficacy Health Water Development Center, 6 public technology centers including Pharmacology and Toxicology Research Center, Drug Analysis Research Center, Clinical Medicine Center, Pharmacy Affairs Center, International R & D Center, Chinese Medicine Quality Inspection Center, Scientific research management, integrated management, human resources, and four scientific research service departments. |
Tasly Research Institute always adheres to the corporate philosophy of “pursuing the integration of heaven and man and improving the quality of life” and the corporate vision of “creating health and sharing for all”, adheres to the large scientific research and development system of “research institutes without walls”, and fully promotes independent research and development. Cooperative R & D, external introduction and investment priority permission "Four in One" innovative R & D model, draw up a blueprint for scientific research according to large varieties, diseases, and fields, through systematic evaluation, achieve value integration of results, and develop comprehensive research and development Enabling innovative products. Implement full life cycle management from product establishment to product listing and product secondary development, effectively linking the respective advantages of "research, production, sales and investment", and build an openness that integrates concept establishment, strategy formulation, scheme design, resource deployment, and results verification. Innovate a large platform and carry out research and development of health products such as Chinese medicine, chemical medicine, biological medicine and other biomedicine and health products, functional foods, cosmetics, modern liquor, bio-puerh tea, and health drinks. In accordance with the requirements of "two rotations and one liter—transition to an innovative enterprise, transition to a smart service enterprise, and upgrade to digital intelligent manufacturing", create talking products to achieve quality and safety assurance, and systemic functional effects. .
| In 2000, the research institute was approved by the Ministry of Personnel to set up an enterprise postdoctoral research workstation. In 2002, it was certified as a national enterprise technology center. In 2006, it was certified as a national research and development center by the Ministry of Science and Technology. In 2007, it was certified as a national enterprise patent work exchange station. Awarded by Tianjin Municipal Science and Technology Commission in 2011 as the Tianjin Key Laboratory of Chinese Medicine Enterprises, and in 2013 the National Joint Research Center for Innovative Drugs. In 2015, the Ministry of Science and Technology approved the “National Key Laboratory of Key Technologies for Innovative Chinese Medicine”, 2015 The National Development and Reform Commission approved the "National and Local Joint Engineering Laboratory for Advanced Manufacturing Technology of Traditional Chinese Medicine" and was awarded the title of "Smart Manufacturing Pilot Demonstration" by the Ministry of Industry and Information Technology in 2016. |
Has successively undertaken or participated in 117 scientific research projects such as the National 863 Plan, 973 Plan, and major new drug creation projects; successively won 4 national science and technology progress awards, 19 provincial and ministerial science and technology progress awards, and 3 national key new products; applied for patent 1815 (PCT97), including 1,526 invention patents (PCT97), 1228 patents (PCT386) have been authorized; 22 monographs, 1536 Chinese core journal papers, and 242 SCI journal papers.
| Under the development concept of "research institutes without walls", through the optimization, integration and reasonable layout of scientific research resources, the research institutes are gradually building research platforms and projects on drug synthesis, preparation, analysis, pharmacological screening, clinical, and domestic and foreign registration. Management platform. Through the construction of research platforms and management platforms, timely create valuable innovative products for the sustainable development of innovative enterprises. |
The Institute adheres to the talent management mechanism of "don't seek but use", implements a dual-channel qualification mode for scientific research and management, clarifies the professional grade promotion channels for scientific researchers, and gradually forms its own technical backbone, core expert team, and joint training The "Trinity" talent model for students. There are 501 scientific researchers, including 96 senior titles, 1 National Thousand Talents Program, 6 experts from the State Council Special Allowance, 25 overseas returnees, 98 doctors and post-doctors, 272 masters, and post-doctors 14 people, 32 doctoral students and 199 postgraduates.
Scientific research management has continuously innovated the management model. Under the guidance of the group's "General, Combat, and Construction" large scientific research organization system, the establishment of a large scientific research system with disease domain as the axis and project as the core, and professional management combined with project management, has achieved Research, production, sales and investment IPD integrated research and development model. Focusing on unmet clinical needs, the research and development system focuses on the development of innovative drugs and the cultivation of large varieties of marketed products, builds a diversified R & D resource allocation model, and accelerates the transformation of innovation results to form a "prominent center, rich wings and complementary advantages, The new pattern of orderly extension and diversified and coordinated development.
Established an industry-university-research laboratory with Tianjin University of Traditional Chinese Medicine, Peking University School of Medicine, Zhejiang University, Second Military Medical University, Dalian University of Technology, Northwest A & F University, Wuhan Yaogu, Tianjin University, Shanghai Huashan Hospital, etc., and Pharnext, France Transgene, South Korea Genexine, etc. have established joint ventures to continuously improve the product research and development technology chain combining industry, university and research, and jointly develop more than 100 new products in the fields of cardio-cerebral vascular, anti-tumor, psycho-immunity, digestive metabolism, antibacterial and antiviral, gynecological and pediatric diseases. 88 clinical approvals, 31 new drug certificates / production approvals, and 21 health food certificates have been approved, and compound Danshen dripping pills, nourishing serum brain granules, Qishen Yiqi dripping pills, and Yiqi Fumai lyophilized powder for injection have been cultivated. A series of modern Chinese medicines such as needles and salvia polyphenolic acids, special chemical medicines such as Tiqing and Wenfei, and innovative biological agents such as Puyouke. The research institute develops innovative ideas for large varieties and product groups, targets the market, combines scientific research innovation and in-depth research, focuses on clinical value and quality advantages, conducts research on large variety mechanisms around disease treatment paths, and taps clinical advantages of products. Create and cultivate large varieties from the entire industrial chain, and form large varieties in the field of disease according to the synergy and complementarity between products.